FDA s COVID-19 PREPP Initiative Summary Report â Key Takeaways For Manufacturers
By Madeleine Giaquinto, Manager of Regulatory Affairs, Greenleaf Health, Inc.
In January 2021, as one of his last official acts as the Commissioner of the FDA, Stephen Hahn, M.D., published the
FDA COVID-19 Pandemic Recovery and Preparedness Plan (PREPP) Initiative Summary Report.
1 The PREPP report is the culmination of work performed by the FDA’s PREPP Initiative, which launched in April 2020 to examine lessons learned from the agency’s response spanning FDA policies, processes, operations, communications, and intra-agency coordination to the global COVID-19 pandemic.
2 The FDA asked an independent non-government organization to conduct an objective review of its ongoing COVID-19 response and to summarize findings in the PREPP report. To that end, the third-party organization solicited insights from key FDA staff and external stakeholders, collated lessons learned, and suggested 12 p
FDA s COVID-19 PREPP Initiative Summary Report — Key Takeaways For Manufacturers
meddeviceonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from meddeviceonline.com Daily Mail and Mail on Sunday newspapers.
FDA s COVID-19 PREPP Initiative Summary Report — Key Takeaways For Manufacturers
pharmaceuticalonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmaceuticalonline.com Daily Mail and Mail on Sunday newspapers.
The future of inspections under FDA’s COVID-19 PREPP initiative (MRI).
On January 13, FDA published a summary report on the agency’s Pandemic Recovery and Preparedness Plan (PREPP) initiative, which was launched internally in April 2020 and announced publicly in August 2020. According to the summary report, the PREPP initiative is aimed at strengthening FDA’s ongoing COVID-19 response and building the agency’s resilience to respond to future emergencies, including by identifying several “broad cross-cutting ‘Action Areas’ that reflect ongoing and potential prospective actions.” Notably, these action areas include “continu[ing] to evolve and optimize inspectional operations, building on the COVID-19 experience as a catalyst” and “strengthen[ing] supply chain surveillance for regulated products,” suggesting that several of FDA’s COVID-related inspection pilot projects will continue into the future.